The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evaluation of diagnostic and prognostic candidate biomarkers in drug‐induced liver injury vs. other forms of acute liver damage
Abstract
Aims: Detection and characterization of idiosyncratic drug‐induced liver injury (DILI) currently rely on standard liver tests, which are suboptimal in terms of specificity, sensitivity and prognosis. Therefore, DILI diagnosis can be delayed, with important consequences for the patient. In this study, we aimed to evaluate the potential of osteopontin, cytokeratin‐18 (caspase‐cleaved: ccK18 and total: K18), α‐glutathione‐S‐transferase and microRNA‐122 as new DILI biomarkers. Methods: Serial blood samples were collected from 32 DILI and 34 non‐DILI acute liver injury (ALI) cases and a single sample from 43 population controls without liver injury (HLC) and analysed using enzyme‐linked immunosorbent assay (ELISA) or single‐molecule arrays. Results: All biomarkers differentiated DILI and ALI from HLC with an area under receiver operator characteristic curve (AUC) value of >0.75 but were less efficient in distinguishing DILI from ALI, with ccK18 (0.79) and K18 (0.76) demonstrating highest potential. However, the AUC improved considerably (0.98) for ccK18 when comparing DILI and a subgroup of autoimmune hepatitis cases. Cytokeratin‐18, microRNA‐122 and α‐glutathione‐S‐transferase correlated well with traditional transaminases, while osteopontin correlated most strongly with the international normalized ratio (INR). Conclusions: ccK18 appears promising in distinguishing DILI from autoimmune hepatitis but less so from other forms of acute liver injury. Osteopontin demonstrates prognostic potential with higher levels detected in more severe cases regardless of aetiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DILI-specific biomarkers have not yet been fully translated into the clinic.
“Although research into the discovery and qualification of DILI‐specific biomarkers has yielded interesting results, these have not yet been fully translated into the clinic”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [13]
International collaborative efforts such as the Safer and Faster Evidence-Based Translation consortium and the Translational Safety Biomarker Pipeline are enabling development and implementation of novel safety biomarkers in clinical trials and early diagnosis of disease, although none have yet been shown to be DILI specific.
“International collaborative efforts such as the Safer and Faster Evidence‐Based Translation consortium, followed by the Translational Safety Biomarker Pipeline, are enabling the development and implementation of novel safety biomarkers in clinical trials and early diagnosis of disease, although none of these have yet been shown to be DILI specific.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationLee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238717 · Cited by 74
Flagged first, then by citations
Research works printed but not linked: 30
- 10.1016/j.jhep.2015.04.016 · DOI
- 10.1002/hep.29152 · DOI · Paper page
- 10.1002/hep.29802 · DOI · Paper page
- 10.7150/ijbs.16445 · DOI
- 10.1158/1535‐7163.MCT‐07‐2136 · DOI
- 10.1097/MPG.0000000000001136 · DOI
- 10.1155/2017/9729107 · DOI
- 10.1097/MEG.0000000000002176 · DOI
- 10.1016/j.alcohol.2006.01.003 · DOI
- 10.1002/hep.26294 · DOI
- 10.1002/hep.29581 · DOI
- 10.1155/2019/5850787 · DOI
- 10.1373/jalm.2016.020412 · DOI
- 10.1055/s‐0034‐1397344 · DOI
- 10.1136/gutjnl‐2020‐322526 · DOI
- 10.1038/clpt.2011.58 · DOI · Paper page
- 10.1371/journal.pone.0179669 · DOI
- 10.1021/acs.analchem.9b05449 · DOI
- 10.1097/MEG.0b013e3283610484 · DOI
- 10.1007/s00204‐021‐03121‐0 · DOI
- 10.1016/S2468‐1253(17)30266‐2 · DOI · Paper page
- US Food AND Drug Administartion, DDT‐BMQ‐000113, Safety biomarker to identify drug‐induced liver injury biomarker panel
- 10.1002/hep.24538 · DOI
- 10.1080/1354750X.2021.2008009 · DOI
- 10.1111/hepr.12166 · DOI
- 10.1016/j.cyto.2015.02.021 · DOI
- 10.1080/00365520510024061 · DOI
- 10.1002/cpt.2423 · DOI
- 10.1002/cpt.2500 · DOI
- 10.1111/liv.15378 · DOI · Paper page
Cited by
Sorted by citations
Methods for causality assessment of idiosyncratic drug‐induced liver injury
García‐Cortés, M., Matilla‐Cabello, G., & Lucena, M. I. (2025) · Liver International · doi:10.1111/liv.16083 · Cited by 15
Self-citation
Metadata
- Authors
- Cueto‐Sánchez, A., Niu, H., Álvarez‐Álvarez, I., López‐Longarela, B., Del Campo‐Herrera, E., Ortega‐Alonso, A., García‐Cortés, M., Pinazo‐Bandera, J., Sanabria‐Cabrera, J., Díaz‐Mochón, J. J., Lucena, M. I., Andrade, R. J., Stephens, C., & Robles‐Díaz, M.
- Affiliations
- UGC de Aparato Digestivo, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga‐IBIMA Plataforma BIONAND, Hospital Universitario Virgen de la Victoria Universidad de Málaga Málaga Spain
- Destina Genomica S.L. Granada Spain
- ORCID
- Lucena, M. Isabel
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2023-04-10
- Volume
- 89
- Issue
- 8
- Pages
- 2497-2507
- ISSN
- 0306-5251
- 1365-2125
- Cited by
- 24
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
